Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
1. Wegovy® significantly reduces heart attack and stroke risks compared to tirzepatide. 2. 57% greater reduction in risks for patients on Wegovy® was reported. 3. Wegovy® stands alone with proven cardiovascular benefits among GLP-1 medications. 4. Study indicates REAL-WORLD effectiveness of Wegovy® for cardiovascular patients. 5. Novo Nordisk reinforces position with strong clinical evidence for Wegovy®.